دورية أكاديمية
أعرض في EDS

Neurobehavioral changes arising from early life dopamine signaling perturbations.

التفاصيل البيبلوغرافية
العنوان: Neurobehavioral changes arising from early life dopamine signaling perturbations.
المؤلفون: Areal LB; Department of Biomedical Science, Florida Atlantic University, Jupiter, FL, 33458, USA., Blakely RD; Department of Biomedical Science, Florida Atlantic University, Jupiter, FL, 33458, USA; Brain Institute, Florida Atlantic University, Jupiter, FL, 33458, USA. Electronic address: rblakely@health.fau.edu.
المصدر: Neurochemistry international [Neurochem Int] 2020 Jul; Vol. 137, pp. 104747. Date of Electronic Publication: 2020 Apr 20.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Review
اللغة: English
بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 8006959 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9754 (Electronic) Linking ISSN: 01970186 NLM ISO Abbreviation: Neurochem Int Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford [Elmsford, N. Y.] Pergamon Press.
مواضيع طبية MeSH: Attention Deficit Disorder with Hyperactivity/*physiopathology , Autism Spectrum Disorder/*physiopathology , Dopamine/*metabolism , Dopamine Plasma Membrane Transport Proteins/*metabolism, Animals ; Autism Spectrum Disorder/metabolism ; Dopamine/physiology ; Humans ; Schizophrenia/physiopathology ; Signal Transduction/drug effects ; Signal Transduction/physiology
مستخلص: Dopamine (DA) signaling is critical to the modulation of multiple brain functions including locomotion, reinforcement, attention and cognition. The literature provides strong evidence that altered DA availability and actions can impact normal neurodevelopment, with both early and enduring consequences on anatomy, physiology and behavior. An appreciation for the developmental contributions of DA signaling to brain development is needed to guide efforts to preclude and remedy neurobehavioral disorders, such as attention-deficit/hyperactivity disorder, addiction, bipolar disorder, schizophrenia and autism spectrum disorder, each of which exhibits links to DA via genetic, cellular and/or pharmacological findings. In this review, we highlight research pursued in preclinical models that use genetic and pharmacological approaches to manipulate DA signaling at sensitive developmental stages, leading to changes at molecular, circuit and/or behavioral levels. We discuss how these alterations can be aligned with traits displayed by neuropsychiatric diseases. Lastly, we review human studies that evaluate contributions of developmental perturbations of DA systems to increased risk for neuropsychiatric disorders.
Competing Interests: Declaration of competing interest None.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
References: Neuropsychopharmacology. 2015 Jan;40(1):88-112. (PMID: 25178408)
Dev Neurosci. 2017;39(5):355-360. (PMID: 28750400)
Trends Genet. 2009 Dec;25(12):528-35. (PMID: 19883952)
J Neurosci. 2018 Apr 11;38(15):3619-3630. (PMID: 29483281)
Curr Psychiatry Rep. 2010 Oct;12(5):382-8. (PMID: 20694583)
J Neurosci. 2018 Feb 21;38(8):1959-1972. (PMID: 29348190)
Behav Brain Res. 2018 Jan 30;337:61-69. (PMID: 28964912)
Brain Res. 2015 Aug 18;1617:144-54. (PMID: 25301689)
Dev Neurobiol. 2007 Dec;67(14):1891-900. (PMID: 17874461)
Eur Neuropsychopharmacol. 2012 Jan;22(1):53-63. (PMID: 21550213)
Brain Res. 2013 Jan 23;1491:236-50. (PMID: 23159831)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2915-20. (PMID: 19202072)
Z Anat Entwicklungsgesch. 1972;137(3):301-16. (PMID: 4674067)
Neuroscience. 2011 Dec 29;199:501-14. (PMID: 22015925)
J Clin Psychiatry. 2016 Oct;77(10):e1205-e1210. (PMID: 27574840)
J Neurosci Res. 1996 Feb 15;43(4):439-53. (PMID: 8699530)
Eur J Neurosci. 2004 Jan;19(1):181-9. (PMID: 14750976)
Science. 2018 Jun 22;360(6395):. (PMID: 29930110)
Front Psychiatry. 2018 Dec 20;9:717. (PMID: 30618886)
J Neurophysiol. 2007 Jul;98(1):423-32. (PMID: 17522168)
Eur J Neurosci. 2008 Oct;28(8):1480-90. (PMID: 18973573)
Int J Dev Neurosci. 2011 May;29(3):225-36. (PMID: 20888897)
Schizophr Bull. 2018 Jun 6;44(4):834-843. (PMID: 28981847)
Neuropsychopharmacology. 2001 Nov;25(5):651-61. (PMID: 11682248)
Dev Cogn Neurosci. 2017 Jun;25:29-44. (PMID: 27840157)
Eur J Neurosci. 2008 Jan;27(2):388-95. (PMID: 18215235)
J Mol Neurosci. 2016 Dec;60(4):453-464. (PMID: 27660217)
BMC Neurosci. 2012 Feb 15;13:18. (PMID: 22336227)
J Neurosci. 2012 Apr 18;32(16):5385-97. (PMID: 22514303)
Nat Neurosci. 2013 Nov;16(11):1627-36. (PMID: 24121738)
Cereb Cortex. 2004 Jun;14(6):665-75. (PMID: 15054047)
Science. 1999 Jan 15;283(5400):397-401. (PMID: 9888856)
J Clin Invest. 2019 May 16;129(8):3407-3419. (PMID: 31094705)
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4245-50. (PMID: 12655058)
Neuron. 2018 Aug 8;99(3):540-554.e4. (PMID: 30057204)
Neurochem Int. 2014 Jul;73:42-8. (PMID: 24231471)
Trends Pharmacol Sci. 2010 Aug;31(8):381-90. (PMID: 20579747)
Brain Struct Funct. 2018 May;223(4):1829-1838. (PMID: 29247260)
Psychopharmacology (Berl). 2017 Apr;234(8):1293-1305. (PMID: 28210781)
P T. 2015 Jun;40(6):389-97. (PMID: 26045648)
Eur Child Adolesc Psychiatry. 2018 Aug;27(8):1067-1075. (PMID: 29497857)
Neuropharmacology. 2017 Feb;113(Pt A):260-270. (PMID: 27732870)
J Neurosci. 2005 Feb 23;25(8):2132-7. (PMID: 15728853)
Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):541-50. (PMID: 17440978)
Neuropsychopharmacology. 2019 Apr;44(5):994-1006. (PMID: 30578419)
Eur J Pharmacol. 2010 Dec 15;649(1-3):202-5. (PMID: 20868667)
J Neurosci. 2008 Jul 9;28(28):7040-6. (PMID: 18614672)
J Neurosci Methods. 2005 Oct 15;148(1):78-87. (PMID: 15939479)
Brain Res Dev Brain Res. 2005 Jun 30;157(2):124-31. (PMID: 15885807)
Annu Rev Neurosci. 2006;29:565-98. (PMID: 16776597)
Neuropharmacology. 2017 Jul 15;121:179-194. (PMID: 28454982)
Int J Mol Sci. 2019 Dec 31;21(1):. (PMID: 31906250)
J Neurosci. 2011 Jan 26;31(4):1471-8. (PMID: 21273431)
J Autism Dev Disord. 2013 Jun;43(6):1459-64. (PMID: 23065101)
Brain Pathol. 2015 Jul;25(4):377-90. (PMID: 25726735)
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4029-34. (PMID: 9520487)
Nature. 2014 Jul 24;511(7510):421-7. (PMID: 25056061)
Curr Opin Neurol. 2003 Dec;16 Suppl 2:S1-2. (PMID: 15129843)
Cell. 2016 Oct 6;167(2):566-580.e19. (PMID: 27716510)
J Comp Neurol. 1988 Mar 1;269(1):58-72. (PMID: 3361004)
Brain Res. 2009 Dec 1;1300:58-64. (PMID: 19747903)
Nature. 1996 Feb 15;379(6566):606-12. (PMID: 8628395)
Drug Alcohol Depend. 1995 Nov;40(1):9-15. (PMID: 8746919)
Front Cell Neurosci. 2013 Dec 19;7:260. (PMID: 24391541)
Cell Rep. 2018 Sep 11;24(11):2838-2856. (PMID: 30208311)
Brain Res. 1984 Jan 16;291(1):164-7. (PMID: 6199080)
Neuroscience. 1988 Jun;25(3):857-87. (PMID: 3405431)
Atten Defic Hyperact Disord. 2010 Mar;2(1):21-30. (PMID: 21432587)
Neuropharmacology. 2005 Nov;49(6):724-36. (PMID: 16171832)
Addict Biol. 2020 Jul;25(4):e12791. (PMID: 31192517)
Cereb Cortex. 2019 Aug 14;29(9):3676-3686. (PMID: 30295713)
Neuropharmacology. 2013 Apr;67:432-43. (PMID: 23231809)
Neuropsychopharmacology. 2010 Jan;35(1):48-69. (PMID: 19776734)
Schizophr Res. 2016 Oct;176(2-3):136-140. (PMID: 27338758)
Hum Genet. 2009 Jul;126(1):51-90. (PMID: 19506906)
Pharmacol Biochem Behav. 1989 Oct;34(2):367-74. (PMID: 2576138)
Mol Psychiatry. 2000 May;5(3):275-82. (PMID: 10889530)
Behav Brain Res. 2015 Mar 15;281:116-24. (PMID: 25496784)
Pediatrics. 2003 Jan;111(1):179-85. (PMID: 12509574)
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4779-88. (PMID: 25331903)
Addict Biol. 2020 Jan;25(1):e12721. (PMID: 30779271)
J Med Toxicol. 2012 Mar;8(1):33-42. (PMID: 22108839)
J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S39-45. (PMID: 18480676)
Mol Neurobiol. 2012 Jun;45(3):605-20. (PMID: 22610946)
Front Syst Neurosci. 2019 Jul 18;13:28. (PMID: 31379523)
PLoS One. 2013 Oct 21;8(10):e78317. (PMID: 24205196)
J Neurosci. 2018 Jun 6;38(23):5302-5312. (PMID: 29739866)
J Neurosci. 2008 Mar 5;28(10):2375-82. (PMID: 18322084)
Nat Commun. 2020 Feb 12;11(1):846. (PMID: 32051403)
Brain Res. 2011 May 16;1390:41-9. (PMID: 21439946)
World J Biol Psychiatry. 2012 Apr;13(4):281-92. (PMID: 22404661)
Nat Neurosci. 2002 Jan;5(1):13-4. (PMID: 11731802)
Pharmacol Biochem Behav. 2018 Oct;173:1-14. (PMID: 30102946)
Neuroscience. 2016 Jan 28;313:174-83. (PMID: 26621120)
Neurobiol Learn Mem. 2016 Apr;130:93-104. (PMID: 26868477)
J Neurodev Disord. 2012 Jul 06;4(1):19. (PMID: 22958744)
Front Psychiatry. 2018 Feb 22;9:43. (PMID: 29520239)
Neuropsychopharmacology. 2015 Mar 13;40(5):1101-12. (PMID: 25336209)
Mol Psychiatry. 2018 Mar;23(3):708-712. (PMID: 28555076)
Brain Res. 2007 Jul 2;1156:31-45. (PMID: 17509542)
Nat Rev Neurosci. 2014 Jan;15(1):63. (PMID: 24301065)
Mol Pharmacol. 2004 Jul;66(1):137-43. (PMID: 15213305)
Dev Neurosci. 2009;31(1-2):95-106. (PMID: 19372691)
Genes Brain Behav. 2007 Jun;6(4):314-20. (PMID: 16848782)
Neurochem Int. 2012 Dec;61(7):986-91. (PMID: 22819794)
Psychopharmacology (Berl). 2011 Jan;213(1):43-52. (PMID: 20848087)
Mol Psychiatry. 2013 Dec;18(12):1315-23. (PMID: 23979605)
Dev Neurobiol. 2013 May;73(5):370-83. (PMID: 23135899)
Brain Res Bull. 1987 Aug;19(2):269-74. (PMID: 3664282)
Dev Neurosci. 1998;20(2-3):125-45. (PMID: 9691188)
Eur J Paediatr Neurol. 2012 Sep;16(5):422-33. (PMID: 22306277)
ACS Chem Neurosci. 2015 Jul 15;6(7):1055-1070. (PMID: 25747116)
Biol Psychiatry. 2007 Jun 15;61(12):1320-8. (PMID: 17157268)
Brain Behav. 2018 Feb 19;8(4):e00939. (PMID: 29670821)
J Psychiatr Brain Sci. 2019;4:. (PMID: 31930173)
Eur J Neurosci. 2014 Feb;39(4):548-56. (PMID: 24236977)
Lancet. 1997 Aug 30;350(9078):638. (PMID: 9288051)
J Mol Neurosci. 2019 Aug;68(4):658-666. (PMID: 31054090)
Trends Neurosci. 2017 Dec;40(12):709-719. (PMID: 29032842)
Biol Psychiatry. 2006 Dec 1;60(11):1171-80. (PMID: 16780809)
Neurotox Res. 2007 Feb;11(2):107-30. (PMID: 17449454)
J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63. (PMID: 23452682)
Pharmacol Biochem Behav. 2015 Apr;131:51-6. (PMID: 25643872)
Lancet. 2009 Jun 13;373(9680):2055-66. (PMID: 19524782)
JAMA Psychiatry. 2013 Jul;70(7):740-9. (PMID: 23754458)
Schizophr Bull. 2009 May;35(3):549-62. (PMID: 19325164)
J Neurophysiol. 2012 Sep;108(6):1620-30. (PMID: 22723669)
Transl Psychiatry. 2014 Oct 14;4:e464. (PMID: 25313507)
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1982-7. (PMID: 11172062)
J Clin Invest. 2009 Jun;119(6):1595-603. (PMID: 19478460)
Ann N Y Acad Sci. 2004 Oct;1025:140-5. (PMID: 15542711)
Sci Rep. 2018 Oct 18;8(1):15349. (PMID: 30337626)
Biol Psychiatry. 2018 Jan 15;83(2):181-192. (PMID: 28720317)
Arch Gen Psychiatry. 2006 Jan;63(1):74-81. (PMID: 16389200)
Front Genet. 2018 Sep 21;9:406. (PMID: 30298087)
Mol Psychiatry. 2017 May;22(5):666-679. (PMID: 28289283)
Mol Psychiatry. 2004 Jul;9(7):711-7. (PMID: 14699430)
Synapse. 2013 Apr;67(4):179-88. (PMID: 23184870)
Science. 2017 Sep 22;357(6357):1255-1261. (PMID: 28882997)
Neuroscience. 1996 Sep;74(2):453-60. (PMID: 8865196)
Neurochem Int. 2014 Jul;73:56-70. (PMID: 24332984)
Cereb Cortex. 2017 Jul 1;27(7):3600-3608. (PMID: 27365296)
Brain Res Mol Brain Res. 2004 Dec 20;132(2):95-104. (PMID: 15582150)
J Neurosci. 2002 Jul 15;22(14):6092-105. (PMID: 12122070)
J Neurosci. 2013 Mar 13;33(11):4913-22. (PMID: 23486962)
Behav Pharmacol. 2008 Feb;19(1):21-7. (PMID: 18195591)
J Am Acad Child Adolesc Psychiatry. 1999 Dec;38(12):1536-43. (PMID: 10596254)
Biol Psychiatry. 2011 Sep 15;70(6):583-92. (PMID: 21571252)
Front Pharmacol. 2014 Oct 27;5:228. (PMID: 25452728)
Trends Pharmacol Sci. 1993 Feb;14(2):43-9. (PMID: 8480373)
Am J Psychiatry. 2008 May;165(5):604-9. (PMID: 18381904)
Brain Sci. 2012 Oct 31;2(4):573-88. (PMID: 24961261)
معلومات مُعتمدة: R01 MH105094 United States MH NIMH NIH HHS
فهرسة مساهمة: Keywords: Dopamine; Neurodevelopment; Neuropsychiatric disorders; Polymorphism; Psychostimulant
المشرفين على المادة: 0 (Dopamine Plasma Membrane Transport Proteins)
VTD58H1Z2X (Dopamine)
تواريخ الأحداث: Date Created: 20200424 Date Completed: 20210709 Latest Revision: 20231103
رمز التحديث: 20231103
مُعرف محوري في PubMed: PMC7261509
DOI: 10.1016/j.neuint.2020.104747
PMID: 32325191
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا